Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Joseph R, Dasari SK, Umamaheswaran S, Mangala LS, Bayraktar E, Rodriguez-Aguayo C, Wu Y, Nguyen N, Powell RT, Sobieski M, Liu Y, Kim MS, Corvigno S, Foster K, Hanjra P, Vu TC, Chowdhury MA, Amero P, Stephan C, Lopez-Berestein G, Westin SN, Sood AK. Joseph R, et al. Among authors: westin sn. Int J Mol Sci. 2024 Jan 20;25(2):1278. doi: 10.3390/ijms25021278. Int J Mol Sci. 2024. PMID: 38279277 Free PMC article.
The rise of genomic profiling in ovarian cancer.
Previs RA, Sood AK, Mills GB, Westin SN. Previs RA, et al. Among authors: westin sn. Expert Rev Mol Diagn. 2016 Dec;16(12):1337-1351. doi: 10.1080/14737159.2016.1259069. Expert Rev Mol Diagn. 2016. PMID: 27828713 Free PMC article. Review.
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. Jazaeri A, et al. Among authors: westin sn. Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10. Gynecol Oncol. 2018. PMID: 30213435 Free PMC article. Review.
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.
Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Labrie M, et al. Among authors: westin sn. Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28. Oncotarget. 2019. PMID: 31191824 Free PMC article.
215 results